Natera Inc NTRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection
Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
Natera Announces Leadership Transition
Natera Reports Third Quarter 2026 Financial Results
Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers
Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability
Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
Natera to Report its Third Quarter Results on November 5, 2026
Trading Information
- Previous Close Price
- $288.48
- Day Range
- $277.23–297.00
- 52-Week Range
- $181.00–437.41
- Bid/Ask
- $287.43 / $287.93
- Shares Outstanding
- 145.00M
- Market Cap
- $41.68B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 343.73
- Price/Sales
- 15.56
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 6,140
- Website
- https://www.natera.com
Valuation
Metric | NTRA |
|---|---|
Price/Earnings (Normalized) | 310.75 |
Price/Book Value | 22.27 |
Price/Sales | 14.06 |
Price/Cash Flow | 119.40 |
Price/Earnings
NTRA
Financial Strength
Metric | NTRA |
|---|---|
Quick Ratio | 2.56 |
Current Ratio | 2.81 |
Interest Coverage | −70.84 |
Quick Ratio
NTRA
Profitability
Metric | NTRA |
|---|---|
Return on Assets (Normalized) | 5.14% |
Return on Equity (Normalized) | 7.46% |
Return on Invested Capital (Normalized) | 5.22% |
Return on Assets
NTRA
Diagnostics & Research Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | LOCK|r<mx#@%M | LOCK|@S% | $256B | |||
| Danaher Corp DHR | LOCK|NGMg#!L | LOCK|Q> | $162B | |||
| IDEXX Laboratories Inc IDXX | LOCK|?D%Q^JM | LOCK|?s | $55B | |||
| Agilent Technologies Inc A | LOCK|$b^HqD< | LOCK|GGw | $49B | |||
| Waters Corp WAT | LOCK|jRZ@%& | LOCK|>^M | $45B | |||
| IQVIA Holdings Inc IQV | LOCK|&L%<<%B | LOCK|?Q<n | $44B | |||
| Mettler-Toledo International Inc MTD | LOCK|#Mr$Hk!Q | LOCK|lBtkQ | $34B | |||
| Labcorp Holdings Inc LH | LOCK|H@G?qvQb | LOCK|FCbG | $30B | |||
| Illumina Inc ILMN | LOCK|ddYNJJQ | LOCK|&B<B | $30B | |||
| Quest Diagnostics Inc DGX | LOCK|Q$^!&g | LOCK|Gtn@ | $29B |